| Grant ID | RP160150 |
| Awarded On | November 19, 2015 |
| Title | Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study |
| Program | Academic Research |
| Award Mechanism | Individual Investigator |
| Institution/Organization | The University of Texas M.D. Anderson Cancer Center |
| Principal Investigator/Program Director | Rivka R Colen |
| Cancer Sites | Brain and Other Nervous System |
| Contracted Amount | $897,627 |
| Lay Summary |
The purpose of the research is to uncover and validate novel, relevant, and clinically meaningful genomic targets that can be subsequently developed into a therapeutic and more personalized treatment for Glioblastoma, the most common primary brain tumor. Currently, the absence of a validated method for early and cost-effective genomic target identification and selection remains a critical barrier to the development of targeted therapeutics and personalized medicine; thus, despite recent advances in novel sequencing and microarray technologies, little progress has been made and the clinical course and everyday life of a cancer patient remains largely unchanged. This study is needed to address... |